MCID: OBS002
MIFTS: 66

Obsessive-Compulsive Disorder malady

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Disorder

Aliases & Descriptions for Obsessive-Compulsive Disorder:

Name: Obsessive-Compulsive Disorder 54 12 52 41 42 14 69
Obsessive-Compulsive Disorder, Protection Against 54 13
Obsessive Compulsive Disorder 12 29
Obsessive Compulsive Behavior 69
Anancastic Neurosis 12

Characteristics:

HPO:

32
obsessive-compulsive disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 164230
Disease Ontology 12 DOID:10933
ICD10 33 F42
ICD9CM 35 300.3
MeSH 42 D009771
NCIt 47 C88411
UMLS 69 C0028768

Summaries for Obsessive-Compulsive Disorder

MedlinePlus : 41 obsessive-compulsive disorder (ocd) is a type of anxiety disorder. if you have ocd, you have frequent, upsetting thoughts called obsessions. to try to control the thoughts, you feel an overwhelming urge to repeat certain rituals or behaviors. these are called compulsions. examples of obsessions are a fear of germs or a fear of being hurt. compulsions include washing your hands, counting, checking on things, or cleaning. with ocd, the thoughts and rituals cause distress and get in the way of your daily life. researchers think brain circuits may not work properly in people who have ocd. it tends to run in families. the symptoms often begin in children or teens. treatments include therapy, medicines, or both. one type of therapy, cognitive behavioral therapy, is useful for treating ocd. nih: national institute of mental health

MalaCards based summary : Obsessive-Compulsive Disorder, also known as obsessive-compulsive disorder, protection against, is related to autism spectrum disorder and personality disorder, and has symptoms including obsessive-compulsive behavior, fatigue and sleep disturbances. An important gene associated with Obsessive-Compulsive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Topiramate and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are Decreased viability and behavior/neurological

Disease Ontology : 12 An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions).

OMIM : 54 Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated... (164230) more...

Wikipedia : 71 Obsessive–compulsive disorder (OCD) is a mental disorder where people feel the need to check things... more...

Related Diseases for Obsessive-Compulsive Disorder

Diseases related to Obsessive-Compulsive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
id Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 30.4 BDNF COMT DRD4 OXT SLC6A3 SLC6A4
2 personality disorder 30.3 BDNF COMT DRD2 DRD4 HTR1A HTR2A
3 thalassemia 30.0 BDNF HTR1A SLC1A1
4 schizophrenia 29.7 BDNF COMT DRD2 DRD4 HTR1A HTR1B
5 multiple personality disorder 29.3 BDNF COMT HTR1A HTR1B HTR2A HTR2C
6 trichotillomania 11.6
7 anxiety disorder 11.5
8 gilles de la tourette syndrome 11.4
9 pandas 11.4
10 succinic semialdehyde dehydrogenase deficiency 11.0
11 basal ganglia disease 11.0
12 chromosome 15q11.2 deletion syndrome 11.0
13 mental retardation, autosomal dominant 23 11.0
14 sydenham chorea 11.0
15 body dysmorphic disorder 10.6
16 panic disorder 10.5
17 obsessive-compulsive personality disorder 10.5
18 generalized anxiety disorder 10.5
19 tic disorder 10.4
20 anorexia nervosa 10.4
21 hypochondriasis 10.4
22 bipolar disorder 10.4
23 pathological gambling 10.4
24 social phobia 10.4
25 nephronophthisis 13 10.4 COMT HTR2A SLC6A4
26 neuronitis 10.3
27 agoraphobia 10.3
28 neurogenic bladder 10.3 HTR2A MAOA SLC6A4
29 euthyroid sick syndrome 10.3 DRD2 HTR2A SLC6A4
30 teratoma with malignant transformation 10.3 BDNF DRD2 HTR2A
31 intracranial cavernous angioma 10.3 DRD2 SLC6A3 SLC6A4
32 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.3 BDNF COMT HTR2A SLC6A4
33 chronic tic disorder 10.3
34 eating disorder 10.3
35 alexithymia 10.3
36 adult brainstem astrocytoma 10.3 HTR1A MAOA SLC6A4
37 c8 deficiency, type ii 10.3 COMT DRD2 DRD4
38 urea cycle disorder 10.3 BDNF COMT DRD2
39 kidney pelvis papillary carcinoma 10.3 HTR1A MAOA SLC6A4
40 lethal congenital contracture syndrome 1 10.3 COMT MAOA SGCE
41 18p deletion syndrome 10.3 DRD2 DRD4 SLC6A3
42 breast reconstruction 10.3 BDNF COMT DRD2
43 polyneuropathy 10.3 HTR1A HTR2A
44 allergic hypersensitivity disease 10.3 DRD2 HTR1A HTR2A
45 attention deficit-hyperactivity disorder 10.3
46 schizotypal personality disorder 10.3
47 mood disorder 10.3
48 vascular cancer 10.3 DRD2 HTR1A HTR2A
49 splenic abscess 10.3 DRD2 HTR2A SLC6A3 SLC6A4
50 mastitis 10.3 DRD4 OXT SLC6A3

Comorbidity relations with Obsessive-Compulsive Disorder via Phenotypic Disease Network (PDN):


Anxiety Disorder Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Obsessive-Compulsive Personality Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Disorder:



Diseases related to Obsessive-Compulsive Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Disorder

Symptoms by clinical synopsis from OMIM:

164230

Clinical features from OMIM:

164230

Human phenotypes related to Obsessive-Compulsive Disorder:

32
id Description HPO Frequency HPO Source Accession
1 obsessive-compulsive behavior 32 HP:0000722

UMLS symptoms related to Obsessive-Compulsive Disorder:


fatigue, sleep disturbances, photophobia, psychiatric symptom, mental and behavioral signs and symptoms, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Obsessive-Compulsive Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.43 BDNF COMT DLGAP3 DRD2 DRD4 HTR1A
2 homeostasis/metabolism MP:0005376 10.2 BDNF COMT DRD2 DRD4 HTR1A HTR2C
3 cardiovascular system MP:0005385 10.13 SGCE SLC6A4 TPH1 TPH2 COMT DRD2
4 growth/size/body region MP:0005378 10.11 BDNF DRD2 HTR1B HTR2C HTR3A OXT
5 endocrine/exocrine gland MP:0005379 10.06 BDNF COMT DRD2 HTR1B HTR2A HTR3A
6 integument MP:0010771 9.96 DLGAP3 DRD2 HTR2C HTR3A OXT BDNF
7 nervous system MP:0003631 9.86 DRD2 DRD4 HTR1A HTR2C HTR3A MAOA
8 muscle MP:0005369 9.81 DRD2 HTR1B HTR2A HTR2C HTR3A SGCE
9 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Obsessive-Compulsive Disorder

Drugs for Obsessive-Compulsive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 342)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4,Phase 3,Phase 2,Early Phase 1 97240-79-4 5284627
2
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
3
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
4
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 942 89594
5
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3 99-66-1 3121
6
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 50-36-2 5760 446220
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
8
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
9
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
10
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 52485-79-7 40400 644073
11
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 93-14-1 3516
12
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2 561-27-3 5462328
13
Methadone Approved Phase 4,Phase 3,Phase 1,Phase 2 76-99-3 4095
14
Acamprosate Approved, Investigational Phase 4,Phase 2,Phase 3 77337-76-9 71158
15
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
16
Clomipramine Approved, Vet_approved Phase 4,Phase 3,Phase 2 303-49-1 2801
17
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
18
Cycloserine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 68-41-7 401 6234
19
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
20
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 54910-89-3 3386
21
Haloperidol Approved Phase 4 52-86-8 3559
22
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
23
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
24
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
25
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
26
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 1 113-45-1 4158
27
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
28
Riluzole Approved, Investigational Phase 4,Phase 2 1744-22-5 5070
29
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
30
Milnacipran Approved Phase 4 92623-85-3 65833
31
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
32
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
33 Piracetam Approved Phase 4,Phase 2,Phase 3 7491-74-9
34
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
35
Ribavirin Approved Phase 4 36791-04-5 37542
36
Memantine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 19982-08-2 4054
37
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
38
Clonidine Approved Phase 4,Phase 3,Phase 1 4205-90-7 2803
39
Baclofen Approved Phase 4,Phase 2 1134-47-0 2284
40
Clozapine Approved Phase 4 5786-21-0 2818
41
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
42
Pramipexole Approved, Investigational Phase 4,Phase 1 104632-26-0 59868 119570
43
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
44
Isoniazid Approved Phase 4 54-85-3 3767
45
Rifapentine Approved Phase 4 61379-65-5 6323497
46
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
47
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
48 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Anti-Obesity Agents Phase 4,Phase 3,Phase 2,Early Phase 1
50 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 643)
id Name Status NCT ID Phase
1 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4
2 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4
3 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4
4 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4
5 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4
6 Divalproex Sodium ER in Adult Autism Unknown status NCT00211796 Phase 4
7 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4
8 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4
9 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
10 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4
11 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4
12 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4
13 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4
14 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4
15 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4
16 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-Compulsive Disorder Patients Completed NCT00564564 Phase 4
17 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
18 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4
19 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4
20 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4
21 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4
22 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4
23 Augmentation in Tx-resistant OCD: an Open Label Trial Completed NCT00590642 Phase 4
24 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4
25 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4
26 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4
27 Escitalopram in Schizophrenia in OCD- Open Label Study Completed NCT00456937 Phase 4
28 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4
29 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4
30 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4
31 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4
32 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4
33 Efficacy of Escitalopram in the Treatment of Internet Addiction Completed NCT00565422 Phase 4
34 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4
35 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4
36 STOP Study: Effectiveness of Zyban in a Clinical Population Completed NCT01015170 Phase 4
37 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
38 Three Year Follow up of a Randomised Controlled Trial (RCT) of an Intervention for Tobacco Dependence Among Those With a Psychotic Illness Completed NCT00350493 Phase 4
39 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4
40 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4
41 Treatment of Hepatitis C in Psychiatric Patients Completed NCT00751426 Phase 4
42 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
43 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4
44 Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism. Completed NCT00368862 Phase 4
45 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
46 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4
47 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4
48 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4
49 ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults Completed NCT00511836 Phase 4
50 Riluzole in Fragile X Syndrome Completed NCT00895752 Phase 4

Search NIH Clinical Center for Obsessive-Compulsive Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: obsessive-compulsive disorder

Genetic Tests for Obsessive-Compulsive Disorder

Genetic tests related to Obsessive-Compulsive Disorder:

id Genetic test Affiliating Genes
1 Obsessive-Compulsive Disorder 29

Anatomical Context for Obsessive-Compulsive Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Disorder:

39
Brain, Cortex, Testes, Subthalamic Nucleus, Skin, Thalamus, Prefrontal Cortex

Publications for Obsessive-Compulsive Disorder

Articles related to Obsessive-Compulsive Disorder:

(show top 50) (show all 1073)
id Title Authors Year
1
Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder. ( 27739347 )
2017
2
Functional and structural connectivity of the amygdala in obsessive-compulsive disorder. ( 28018851 )
2017
3
Epidemiology and comorbidity of obsessive-compulsive disorder in late adolescence: a cross-sectional study in senior high schools in Greece. ( 28504027 )
2017
4
Co-morbid obsessive-compulsive disorder and depression: a Bayesian network approach. ( 28052778 )
2017
5
Neurocognitive Function in Pediatric Obsessive-Compulsive Disorder. ( 28090807 )
2017
6
Increased fronto-striatal reward prediction errors moderate decision making in obsessive-compulsive disorder. ( 28065182 )
2017
7
Investigating the role of anticipatory reward and habit strength in obsessive-compulsive disorder. ( 28065178 )
2017
8
New Directions in the Use of Brain Stimulation Interventions in Patients with Obsessive-Compulsive Disorder. ( 28474552 )
2017
9
Prevalence and correlates of obsessive-compulsive disorder and subthreshold obsessive-compulsive disorder among college students in Kerala, India. ( 28529361 )
2017
10
The development and validation of static and adaptive screeners to measure the severity of panic disorder, social anxiety disorder, and obsessive compulsive disorder. ( 28370638 )
2017
11
Cost-effectiveness of therapist-guided internet-delivered cognitive behaviour therapy for paediatric obsessive-compulsive disorder: results from a randomised controlled trial. ( 28515196 )
2017
12
Cost-effectiveness of deep brain stimulation versus treatment as usual for obsessive-compulsive disorder. ( 28457837 )
2017
13
Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis. ( 28477500 )
2017
14
Rare Synaptogenesis-Impairing Mutations in SLITRK5 Are Associated with Obsessive Compulsive Disorder. ( 28085938 )
2017
15
Planning functioning and impulsiveness in obsessive-compulsive disorder. ( 28466133 )
2017
16
Shared and disorder-specific task-positive and default mode network dysfunctions during sustained attention in paediatric Attention-Deficit/Hyperactivity Disorder and obsessive/compulsive disorder. ( 28529874 )
2017
17
Embracing Uncertainty as a First-Year Therapist Treating a Patient Who Has Obsessive-Compulsive Disorder. ( 28457206 )
2017
18
L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. ( 28485008 )
2017
19
Unpacking the role of self-reported compulsivity and impulsivity in obsessive-compulsive disorder. ( 28487007 )
2017
20
Anxiety sensitivity as a predictor of outcome in the treatment of obsessive-compulsive disorder. ( 28505489 )
2017
21
Vitamin B12, folic acid, homocysteine and vitamin D levels in children and adolescents with obsessive compulsive disorder. ( 28477545 )
2017
22
Choreatic side-effects of deep brain stimulation of the anteromedial subthalamic nucleus for treatment-resistant obsessive-compulsive disorder: a case report. ( 28532905 )
2017
23
Face and Object Perception in Body Dysmorphic Disorder versus Obsessive-Compulsive Disorder: The Mooney Faces Task. ( 28528596 )
2017
24
Volitional saccade performance in a large sample of patients with obsessive-compulsive disorder and unaffected first-degree relatives. ( 28481032 )
2017
25
Overvalued ideation in adolescents with obsessive-compulsive disorder. ( 28528243 )
2017
26
Deep brain stimulation of the anterior limb of the internal capsule for treatment of therapy-refractory obsessive compulsive disorder (OCD): a case study highlighting neurocognitive and psychiatric changes. ( 28457185 )
2017
27
A cross-cultural clinical comparison between subjects with obsessive-compulsive disorder from the United States and Brazil. ( 28457988 )
2017
28
Resting-state functional connectivity between right anterior insula and right orbital frontal cortex correlate with insight level in obsessive-compulsive disorder. ( 28458998 )
2017
29
Pathophysiology of refractory obsessive-compulsive disorder: A study of visual search combined with overactive performance monitoring. ( 28072701 )
2017
30
Efficacy of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder: A Meta-Analysis. ( 27182928 )
2016
31
Relationships between neuropsychological variables and factor-analysed symptom dimensions in obsessive compulsive disorder. ( 28063400 )
2016
32
Behavioral Impulsivity in Obsessive-Compulsive Disorder. ( 27156379 )
2016
33
Tolosa-Hunt syndrome and comorbidity of obsessive compulsive disorder and aortic aneurysm. ( 27872048 )
2016
34
Use of Selective Serotonin Reuptake Inhibitors and Risks of Stroke in Patients with Obsessive Compulsive Disorder: A Population-Based Study. ( 27612144 )
2016
35
Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. ( 27459640 )
2016
36
Association between the Catechol-O-Methyltransferase (COMT) ValA^a8/a8,Met Polymorphism and Alexithymia in Patients with Obsessive-Compulsive Disorder. ( 26996573 )
2016
37
Pediatric Obsessive-Compulsive Disorder Exacerbation and Obstructive Hydrocephalus: A Case Report. ( 27609824 )
2016
38
A Case Report of Harm-Related Obsessions in Pediatric Obsessive-Compulsive Disorder. ( 27642156 )
2016
39
Cortical thickness in obsessive-compulsive disorder: multisite mega-analysis of 780 brain scans from six centres. ( 27198485 )
2016
40
Excessive nest building is a unique behavioural phenotype in the deer mouse model of obsessive-compulsive disorder. ( 27154874 )
2016
41
Hyperactive performance monitoring as a transdiagnostic marker: Results from health anxiety in comparison to obsessive-compulsive disorder. ( 28041946 )
2016
42
Introduction: Cognitive-Behavioral Treatment for Pediatric Obsessive-Compulsive Disorder. ( 27627740 )
2016
43
Abnormal resting-state functional connectivity of the left caudate nucleus in obsessive-compulsive disorder. ( 27143323 )
2016
44
Comparison of cognitive flexibility and planning ability in patients with obsessive compulsive disorder, patients with obsessive compulsive personality disorder, and healthy controls. ( 27688641 )
2016
45
Pediatric obsessive-compulsive disorder with tic symptoms: clinical presentation and treatment outcome. ( 28032202 )
2016
46
Polymorphisms within the neuronal cadherin (CDH2) gene are associated with obsessive-compulsive disorder (OCD) in a South African cohort. ( 26093892 )
2016
47
Decisional impulsivity and the associative-limbic subthalamic nucleus in obsessive-compulsive disorder: stimulation and connectivity. ( 28040671 )
2016
48
The Impact of Obsessive Compulsive Personality Disorder on Cognitive Behaviour Therapy for Obsessive Compulsive Disorder. ( 27246860 )
2016
49
Prevalence and correlates of electroconvulsive therapy delivery in 1001 obsessive-compulsive disorder outpatients. ( 27137976 )
2016
50
TRANSGENDER ANXIETY, CULTURAL ISSUES, AND CANNABIS IN OBSESSIVE COMPULSIVE DISORDER. ( 27214301 )
2016

Variations for Obsessive-Compulsive Disorder

Copy number variations for Obsessive-Compulsive Disorder from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 77765 13 47471310 47471410 Deletion Obsessive-compulsive disorder
2 160222 22 11800000 24300000 Deletion Obsessive-compulsive disorder

Expression for Obsessive-Compulsive Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Disorder.

Pathways for Obsessive-Compulsive Disorder

Pathways related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 COMT DLGAP3 MAOA SLC1A1 SLC6A3 SLC6A4
2
Show member pathways
12.6 COMT DRD2 DRD4 MAOA SLC1A1 SLC6A3
3 12.4 COMT HTR1A SLC1A1 TPH1 TPH2
4
Show member pathways
12.13 BDNF DRD2 HTR1A HTR1B
6 11.97 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
7
Show member pathways
11.85 BDNF DRD2 MAOA SLC6A3
8
Show member pathways
11.79 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
9 11.66 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
10
Show member pathways
11.3 MAOA SLC6A3 SLC6A4 TPH2
11
Show member pathways
11.05 COMT MAOA SLC6A3 SLC6A4
12
Show member pathways
10.95 COMT MAOA TPH1
13 10.86 HTR2A HTR2C
14 10.72 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
15 10.69 COMT MAOA
16
Show member pathways
10.68 COMT MAOA

GO Terms for Obsessive-Compulsive Disorder

Cellular components related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 COMT DLGAP3 DRD2 DRD4 HTR1A HTR1B
2 axon GO:0030424 9.55 COMT DRD2 HTR2A HTR3A SLC6A3
3 integral component of plasma membrane GO:0005887 9.32 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
4 integral component of membrane GO:0016021 10.1 COMT DRD2 DRD4 HTR1A HTR1B HTR2A

Biological processes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.98 HTR1B HTR2A HTR2C SLC1A1
2 cellular calcium ion homeostasis GO:0006874 9.89 DRD4 HTR2A HTR2C
3 locomotory behavior GO:0007626 9.88 DRD2 HTR2C SLC6A3
4 circadian rhythm GO:0007623 9.88 SLC6A4 TPH1 TPH2
5 response to ethanol GO:0045471 9.88 DRD2 HTR1B HTR3A SLC6A3
6 memory GO:0007613 9.84 HTR2A OXT SLC6A4
7 synapse assembly GO:0007416 9.83 BDNF DRD2 SLITRK1
8 positive regulation of synapse assembly GO:0051965 9.83 BDNF OXT SLITRK1
9 social behavior GO:0035176 9.8 DRD4 OXT SLC6A4
10 positive regulation of fat cell differentiation GO:0045600 9.8 HTR2A HTR2C TPH1
11 response to drug GO:0042493 9.8 COMT DRD2 HTR1B HTR2A HTR2C SLC6A3
12 feeding behavior GO:0007631 9.79 DRD2 HTR1B HTR2C
13 release of sequestered calcium ion into cytosol GO:0051209 9.77 DRD2 HTR2A HTR2C
14 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD4
15 response to iron ion GO:0010039 9.72 DRD2 SLC6A3
16 negative regulation of cAMP biosynthetic process GO:0030818 9.72 DRD4 HTR1B
17 positive regulation of kinase activity GO:0033674 9.72 DRD4 HTR2A
18 behavioral fear response GO:0001662 9.72 DRD4 HTR1A HTR2C
19 behavioral response to ethanol GO:0048149 9.71 DRD2 DRD4
20 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
21 grooming behavior GO:0007625 9.71 DRD2 OXT
22 ammonium transmembrane transport GO:0072488 9.71 SLC6A3 SLC6A4
23 response to amphetamine GO:0001975 9.71 DRD2 DRD4 OXT
24 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
25 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 OXT
26 negative regulation of protein secretion GO:0050709 9.7 DRD2 DRD4
27 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD2 DRD4
28 bone remodeling GO:0046849 9.69 HTR1B TPH1
29 G-protein coupled receptor internalization GO:0002031 9.69 DRD2 HTR1B
30 regulation of dopamine secretion GO:0014059 9.69 DRD2 HTR1B HTR2A
31 sleep GO:0030431 9.68 HTR2A OXT
32 neurotransmitter catabolic process GO:0042135 9.68 COMT MAOA
33 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD4
34 catecholamine metabolic process GO:0006584 9.67 COMT MAOA
35 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
36 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
37 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD4 HTR2A
38 aromatic amino acid family metabolic process GO:0009072 9.66 TPH1 TPH2
39 drinking behavior GO:0042756 9.65 HTR1B OXT
40 vasoconstriction GO:0042310 9.65 HTR1A HTR1B SLC6A4
41 sperm ejaculation GO:0042713 9.64 OXT SLC6A4
42 regulation of hormone secretion GO:0046883 9.64 HTR1A HTR2A
43 dopamine uptake involved in synaptic transmission GO:0051583 9.63 SLC6A3 SLC6A4
44 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.63 DRD2 HTR1B HTR2A
45 indolalkylamine biosynthetic process GO:0046219 9.62 TPH1 TPH2
46 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.61 HTR1A HTR1B
47 dopamine metabolic process GO:0042417 9.61 COMT DRD2 DRD4
48 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.6 HTR2A HTR2C
49 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD2 DRD4
50 regulation of dopamine metabolic process GO:0042053 9.58 DRD4 HTR1A SLC6A3

Molecular functions related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.85 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
2 symporter activity GO:0015293 9.73 SLC1A1 SLC6A3 SLC6A4
3 drug binding GO:0008144 9.63 DRD2 DRD4 HTR1B HTR2A HTR2C SLC6A3
4 neurotransmitter receptor activity GO:0030594 9.56 HTR1A HTR1B HTR2A HTR2C
5 neurotransmitter:sodium symporter activity GO:0005328 9.55 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD2 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A3 SLC6A4
8 dopamine binding GO:0035240 9.5 DRD2 DRD4 SLC6A3
9 dopamine neurotransmitter receptor activity GO:0004952 9.49 DRD2 DRD4
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.48 TPH1 TPH2
11 dopamine:sodium symporter activity GO:0005330 9.46 SLC6A3 SLC6A4
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.43 HTR2A HTR2C
13 tryptophan 5-monooxygenase activity GO:0004510 9.4 TPH1 TPH2
14 G-protein coupled serotonin receptor activity GO:0004993 9.35 HTR1A HTR1B HTR2A HTR2C HTR3A
15 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C HTR3A
16 G-protein coupled receptor activity GO:0004930 10.01 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C

Sources for Obsessive-Compulsive Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....